Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: KAKALAK who wrote (4730)	1/17/2000 12:10:00 PM
From: Kingfisher	Read Replies (1) \| Respond to of 4891

KAKA, I'm like most posters, I have difficulty in fully expressing my opinions on this thread. So let me try one more time. Dr. Ralph Thompson's experience with Reticulose in treating influenza was only one aspect of the body of anecdotal information available in September 1960 which attested to the efficacy of Reticulose and its non-toxicity. At that time it was widely know that Reticulose was effective in the treatment of Influenza A, a fact that was finally verified by the FDA itself in 1989* some 29 years later. To summarily dismiss that body of information in 1962 based on it being anecdotal and to further deem Reticulose a new 30-year old drug is like putting you head in the sand. IMHO, it reeks of a total lack of concern for the medical well being of the public and it further fostered the appearance of total incompetence or total corruption. If the present FDA were to attempt to vindicate their wrongful 1962 action based on the continuing evidence of the efficacy and non-toxicity of Reticulose and show some empathy for the public's battle with the influenza epidemic going on today, they could do so by approving Reticulose as an emergency treatment to combat the present situation. After all, if they can sanction the use of the anthrax vaccine they can sanction the use of Reticulose for emergency purposes where there should be no outrage, but rather praise, from the public or the press. *NIH report ARB No. 89-048 of 12 October 1989, by Christopher Tseng, Phd, contains the results of the successful invitro testing of Reticulose against Influenza A.